Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?

The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting...

Descripción completa

Detalles Bibliográficos
Autor principal: Malek, Alexandre E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781165/
https://www.ncbi.nlm.nih.gov/pubmed/33398065
http://dx.doi.org/10.1038/s41416-020-01195-8
_version_ 1783631626776870912
author Malek, Alexandre E.
author_facet Malek, Alexandre E.
author_sort Malek, Alexandre E.
collection PubMed
description The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting in cytokine storm, respiratory failure and severe outcomes.
format Online
Article
Text
id pubmed-7781165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77811652021-01-05 Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era? Malek, Alexandre E. Br J Cancer Comment The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting in cytokine storm, respiratory failure and severe outcomes. Nature Publishing Group UK 2021-01-04 2021-03-30 /pmc/articles/PMC7781165/ /pubmed/33398065 http://dx.doi.org/10.1038/s41416-020-01195-8 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/ Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Comment
Malek, Alexandre E.
Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title_full Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title_fullStr Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title_full_unstemmed Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title_short Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
title_sort time to revisit the use of g-csf after allogeneic haematopoietic cell transplantation in covid-19 era?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781165/
https://www.ncbi.nlm.nih.gov/pubmed/33398065
http://dx.doi.org/10.1038/s41416-020-01195-8
work_keys_str_mv AT malekalexandree timetorevisittheuseofgcsfafterallogeneichaematopoieticcelltransplantationincovid19era

Ejemplares similares